专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007084253A2 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
标题翻译： HMGB1的高亲和力抗体及其使用方法
公开(公告)号：WO2007084253A2
公开(公告)日：2007-07-26
申请号：PCT/US2006/061258
申请日：2006-11-27
申请人： MEDIMMUNE, INC. , CRITICAL THERAPEUTICS , WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , MAO, Su-yau , COYLE, Anthony , TIAN, Jane , O'KEEFE, Theresa , QIN, Shixin
发明人： WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , MAO, Su-yau , COYLE, Anthony , TIAN, Jane , O'KEEFE, Theresa , QIN, Shixin
IPC分类号： A61K39/395 , C07K16/40
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/32
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
摘要翻译：公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症，内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。此外，本发明的高亲和力抗体可用作诊断抗体。

2. 发明申请

WO2008055206A3 HUMANIZED ANTI-FACTOR D ANTIBODIES 审中-公开
标题翻译：人类抗原D抗体
公开(公告)号：WO2008055206A3
公开(公告)日：2008-09-04
申请号：PCT/US2007083172
申请日：2007-10-31
申请人： GENENTECH INC , WU HERREN , SINGH SANJAYA , FUNG SEK CHUNG , AN LING-LING , LOWMAN HENRY B , KELLEY ROBERT F
发明人： WU HERREN , SINGH SANJAYA , FUNG SEK CHUNG , AN LING-LING , LOWMAN HENRY B , KELLEY ROBERT F
IPC分类号： C07K16/36 , A61P27/02 , A61P37/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及人源化抗人因子D单克隆抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其在制备用于治疗与过度或不受控制的疾病和病症的组合物和药物中的用途补体激活。这些抗体可用于疾病的诊断，预防和治疗。

3. 发明申请

WO2008055206A9 HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：人源化抗因子D抗体及其用途
公开(公告)号：WO2008055206A9
公开(公告)日：2008-07-17
申请号：PCT/US2007083172
申请日：2007-10-31
申请人： GENENTECH INC , WU HERREN , SINGH SANJAYA , FUNG SEK CHUNG , AN LING-LING , LOWMAN HENRY B , KELLEY ROBERT F
发明人： WU HERREN , SINGH SANJAYA , FUNG SEK CHUNG , AN LING-LING , LOWMAN HENRY B , KELLEY ROBERT F
IPC分类号： C07K16/36 , A61P27/02 , A61P37/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及人源化抗人因子D单克隆抗体，它们的核酸和氨基酸序列，含有这些抗体的细胞和载体以及它们在制备组合物和药物中的用途，所述组合物和药物用于治疗与过量或不受控制的疾病和病症补体激活。这些抗体可用于诊断，预防和治疗疾病。

4. 发明申请

WO2007076200A3 ANTAGONISTS OF HMGB1 AND/OR RAGE AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007076200A3
公开(公告)日：2007-07-05
申请号：PCT/US2006/061257
申请日：2006-11-27
申请人： MEDIMMUNE, INC. , WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , COYLE, Anthony , TIAN, Jane
发明人： WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , COYLE, Anthony , TIAN, Jane
IPC分类号： A61K39/395 , G01N33/564
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, lupus, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

5. 发明申请

WO2007076200A2 ANTAGONISTS OF HMGB1 AND/OR RAGE AND METHODS OF USE THEREOF 审中-公开
标题翻译： HMGB1和/或RAGE的拮抗剂及其使用方法
公开(公告)号：WO2007076200A2
公开(公告)日：2007-07-05
申请号：PCT/US2006061257
申请日：2006-11-27
申请人： MEDIMMUNE INC , WU HERREN , GAO CHANGSHOU , AN LING-LING , KIENER PETER , COYLE ANTHONY , TIAN JANE
发明人： WU HERREN , GAO CHANGSHOU , AN LING-LING , KIENER PETER , COYLE ANTHONY , TIAN JANE
IPC分类号： A61K39/395
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/32
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, lupus, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
摘要翻译：公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血病，内毒素性休克，囊性纤维化，心内膜炎，狼疮，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。此外，本发明的高亲和力抗体可用作诊断抗体。

6. 发明申请

WO2003035695A3 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
公开(公告)号：WO2003035695A3
公开(公告)日：2003-05-01
申请号：PCT/US2002/023645
申请日：2002-07-25
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/28
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255 Cys-Arg-Arg 2 58 Cys (as CRRC) or at 265 Cys-Met-GIu 2 68 Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.

7. 发明申请

WO2008055206A2 HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：人类抗因子D抗体及其用途
公开(公告)号：WO2008055206A2
公开(公告)日：2008-05-08
申请号：PCT/US2007/083172
申请日：2007-10-31
申请人： GENENTECH, INC. , WU, Herren , SINGH, Sanjaya , FUNG, Sek, Chung , AN, Ling-ling , LOWMAN, Henry, B. , KELLEY, Robert, F.
发明人： WU, Herren , SINGH, Sanjaya , FUNG, Sek, Chung , AN, Ling-ling , LOWMAN, Henry, B. , KELLEY, Robert, F.
IPC分类号： C07K16/36 , A61P37/00 , A61P27/02
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及人源化抗人因子D单克隆抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其在制备用于治疗与过度或不受控制的疾病和病症的组合物和药物中的用途补体激活。这些抗体可用于疾病的诊断，预防和治疗。

8. 发明申请

WO2007001422A3 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007001422A3
公开(公告)日：2007-01-04
申请号：PCT/US2005/037734
申请日：2005-10-21
申请人： MEDIMMUNE, INC. , WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
发明人： WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
IPC分类号： A61K39/395 , G01N33/53
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

9. 发明申请

WO2007001422A2 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
标题翻译： HMGB1的高亲和力抗体及其使用方法
公开(公告)号：WO2007001422A2
公开(公告)日：2007-01-04
申请号：PCT/US2005037734
申请日：2005-10-21
申请人： MEDIMMUNE INC , WU HERREN , ALLAN CHRISTIAN B , GAO CHANGSHOU , AN LING-LING , KIENER PETER , MAO SU-YAU , COYLE ANTHONY
发明人： WU HERREN , ALLAN CHRISTIAN B , GAO CHANGSHOU , AN LING-LING , KIENER PETER , MAO SU-YAU , COYLE ANTHONY
IPC分类号： A61K39/395 , C07K16/40
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
摘要翻译：公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。此外，本发明的高亲和力抗体可用作诊断抗体。

10. 发明申请

WO2003035695A2 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
标题翻译：激活或抑制类似感受器的药剂9
公开(公告)号：WO2003035695A2
公开(公告)日：2003-05-01
申请号：PCT/US2002/023645
申请日：2002-07-25
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/55516 , A61K2039/55561
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255 Cys-Arg-Arg 2 58 Cys (as CRRC) or at 265 Cys-Met-GIu 2 68 Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.
摘要翻译：本发明包括与TLR9上的肽段结合并模拟CpG基序的作用的分子。 CpG模拟剂包括但不限于抗体，小分子化合物，肽，肽模拟物和核酸，包括组合物，其包含结合TLR9上的肽段的分子，并模拟适合于给予需要治疗的患者，任选地与例如赋形剂，稀释剂或载体组合。此外，本发明包括在255Cys-Arg-Arg 258Cys作为CRRC或作为CMEC的265Cys-Met-Glu 268Cys与TLR9的CXXC基序结合的那些分子。本发明包括通过诱导Th1型应答来调节免疫应答的方法，包括施用结合TLR9并模拟CpG功能的分子。这些分子也将宿主细胞反应从Th2型反应转移到Th1型反应。因此，施用结合TLR9的本发明的分子可以避免Th2介导的免疫诱导的过敏反应的风险，使得该方法可用于免疫治疗和哮喘治疗。本发明的分子可以与特定的变应原组合施用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式